JIPOAd
PARP
ESID
  • Users Online: 358
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2019| July-September  | Volume 2 | Issue 3  
    Online since August 22, 2019

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EXPERT OPINION
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data
Katherine A Scilla, Alessandro Russo, Christian Rolfo
July-September 2019, 2(3):55-58
DOI:10.4103/JIPO.JIPO_13_19  
  1,012 74 -
REVIEW ARTICLES
Kaposi's sarcoma in the immunosuppressed
Nisha A Reddy, Steven R Mays, Omar Pacha
July-September 2019, 2(3):74-78
DOI:10.4103/JIPO.JIPO_10_19  
  869 70 -
ORIGINAL RESEARCH
Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders
Mohsin Shah, Mazen N Jizzini, Imad E Majzoub, Aiham Qdaisat, Cielito C Reyes-Gibby, Sai-Ching Yeung
July-September 2019, 2(3):59-64
DOI:10.4103/JIPO.JIPO_11_19  
  814 86 -
REVIEW ARTICLES
Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review
Ahmad Daher, Carlos Kamiya Matsuoka, Monica Elena Loghin, Marta Penas-Prado, Sudhakar Tummala
July-September 2019, 2(3):93-100
DOI:10.4103/JIPO.JIPO_3_19  
  812 64 -
EDITORIAL
Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy
Joud Hajjar
July-September 2019, 2(3):53-54
DOI:10.4103/JIPO.JIPO_15_19  
  762 105 2
ORIGINAL RESEARCH
Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States Food and Drug Administration adverse event reporting system
Xerxes N Pundole, Mayur Sarangdhar, Maria E Suarez-Almazor
July-September 2019, 2(3):65-73
DOI:10.4103/JIPO.JIPO_12_19  
  779 71 -
CASE REPORT
Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer
Yacine Wissam, Laila Belcaid, Ruth Wittoek, Vanessa Smith, Amber Vanhaecke, Sofie De Schepper, Lennart Jans, Daphné t'Kint de Roodenbeke, Andrea Gombos, Sandrine Aspeslagh
July-September 2019, 2(3):101-105
DOI:10.4103/JIPO.JIPO_8_19  
  742 44 -
CONFERENCE PROCEEDINGS
Meeting Proceedings of the First Immuno-Oncology Society of India Conference (I-OSICON-2019), Mumbai, India
Jyoti Bajpai, Ram Abhinav Kannan, Hemant Malhotra, Vivek Radhakrishnan, Rakesh Jalali, Gaurav Narula, Amit Awasthi, Girdhari Lal, Rahul Purvar, Kumar Prabhash, Senthil Rajappa, Atul Sharma, Moni Kuriakose, Vikram Matthews, Reena Nair, Smruti Koppikar, Shubhda V Chiplunkar, Shripad Banavali
July-September 2019, 2(3):106-125
DOI:10.4103/2666-2345.265156  
  584 53 -
REVIEW ARTICLES
Common cutaneous neoplasms in patients with immunodeficiency: A case series
Suhair Al Salihi, Haider A Mejbel, Victor G Prieto, Phyu P Aung
July-September 2019, 2(3):79-84
DOI:10.4103/JIPO.JIPO_9_19  
  475 32 -
Review: The impact of HIV infection on cancer treatment with immunotherapy
Bruno Palma Granwehr
July-September 2019, 2(3):85-92
DOI:10.4103/JIPO.JIPO_14_19  
  376 29 -